DXSP DXS International PLC

Director/PDMR Shareholding

Director/PDMR Shareholding

DXS INTERNATIONAL PLC

Notification of Director / PDMR Dealing

The Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification that on 18 November 2022 Mr David Immelman, the Chief Executive and DL Services Limited, a company owned and controlled by his wife, purchased a total of 50,084 Ordinary Shares in the Company at a price of 5.454p per share.

Following the transaction specified above Mr Immelman’s interests, including those of persons closely associated with him, is 5,770,585 Ordinary Shares representing 11.96% of the issued share capital of the Company.

1



 
Details of the person discharging managerial responsibilities / person closely associated
a)



 
Name



 
David Immelman



 
2 Reason for the notification
a)



 
Position/status



 
Chief Executive
b)



 
Initial notification /Amendment



 
Initial
3



 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor



 
a)



 
Name



 



 
DXS INTERNATIONAL PLC
b)



 
LEI



 



 
2138001R1KEUWTXEVJ44
4



 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)



 



 



 



 
Description of the financial instrument, type of instrument Ordinary Shares of 0.33p each
  
Identification code ISIN GB00B2Q6HZ92
  
b)



 
Nature of the transaction



 
Purchase
c)



 



 



 



 
Price(s) and volume(s)     
  Price(s)Volume(s) 
  5.454p50,084 
     
d)



 



 



 



 



 



 
Aggregated information  
  
- Aggregated volume 
  
- Price 
  
e)



 
Date of the transaction



 



 
18 November 2022
f)



 
Place of the transaction



 



 
AQSE

The Directors of DXS International plc accept responsibility for this announcement

Enquiries:

David Immelman      (Chief Executive)

DXS International plc
01252 719800

Wrecclesham House

Wrecclesham Road

Farnham

Surrey

GU10 4PS
 
-systems.co.uk 



Corporate Advisor



 
 
David Papworth

City & Merchant
0207 101 7676



 



Corporate Broker



 
 
Hybridan LLP

Claire Louise Noyce



 
020 3764 2341



 

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.



EN
22/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DXS International PLC

 PRESS RELEASE

DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meet...

DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting Monday 24 November DXS INTERNATIONAL PLC (AQSE: DXSP) Notice of 2025 Annual General Meeting The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that its Annual General Meeting is scheduled to take place on Thursday 18th December at 11.30 at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB. For further information in relation to the AGM, shareholders should...

 PRESS RELEASE

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dea...

DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 11 November, Mr Bob Sutcliffe, the Chairman, purchased 50,000 Ordinary Shares in the Company at a price of 1.30p per share. Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares...

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Hybridan Research: DXS International plc: NHS Opportunity Remains

Despite bureaucratic headaches, the final results to 30 April report a 5% increase in revenue to £3.5m and a reduced loss to £94.8k. The P&L comparison with 2024 is awkward due to changes in accounting practises and the £4.7m impairment charge. The FY 2025 loss was affected by a sharp decline in allowable R&D which was down to £80k from £212k due to HMRC’s new restrictions on overseas development. DXS continues to significantly invest in innovation and developing solutions. These costs are now ...

 PRESS RELEASE

DXS International plc ((AQSE: DXSP) - Final Results

DXS International plc ((AQSE: DXSP) - Final Results DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2025 The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2025. Financial highlights: Revenue increased by 5% to £3,469,917 (2024: £3,308,359). Core recurring revenue model remains resilient.Available cash at the period end was £428,957 plus unutilised debtor drawdowns of £2...

 PRESS RELEASE

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK ...

DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare featured in Innovate UK Research Project DXS International plc ("DXS" or "the Company"), a leading provider of digital clinical decision support solutions, is thrilled to announce that its leading-edge digital health solution, ExpertCare, has been independently reviewed by the prestigious York Health Economics Consortium (YHEC) with results that confirm its powerful impact on both clinical outcomes and NHS cost-efficiency.  Funded by DXS and Innovate UK and...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch